Therapeutic Drug Monitoring of Imatinib

Background The imatinib trough plasma concentration (Cmin) correlates with clinical response in cancer patients. Therapeutic drug monitoring (TDM) of plasma Cmin is therefore suggested. In practice, however, blood sampling for TDM is often not performed at trough. The corresponding measurement is thus only remotely informative about Cmin exposure.